Hexagon Pipeline: ADCs with novel payload mechanisms
Hexagon Bio is advancing a pipeline of next-generation ADCs with novel payloads that address unmet needs in solid tumors. Our lead programs leverage novel Protein Translation Inhibitor (PTI) payloads and dual-payload strategies to address resistance to existing payloads and open new opportunities for ADCs in multiple cancer types.
Payload Mechanism
Program
Target / Indication
Discovery
Preclinical
IND-Enabling
Phase 1
Novel Protein Translation Inhibitor (PTI) Payload
HEX-360
HER2 (Solid Tumors)
ADC 2
Undisclosed (Solid Tumors)
ADC 3
Undisclosed (Solid Tumors)
Dual Payloads
Dual Combo 1
Undisclosed (Solid Tumors)
Novel Payload Discovery
Novel Payload MoAs
Platform Research